KeyCorp Reaffirms Sector Weight Rating for Harvard Bioscience (NASDAQ:HBIO)

Harvard Bioscience (NASDAQ:HBIO)‘s stock had its “sector weight” rating reissued by equities researchers at KeyCorp in a research report issued to clients and investors on Wednesday, MarketBeat Ratings reports.

Separately, Benchmark decreased their price objective on Harvard Bioscience from $5.50 to $4.50 and set a “speculative buy” rating on the stock in a report on Monday, March 24th.

Harvard Bioscience Stock Down 16.0 %

HBIO opened at $0.39 on Wednesday. The business’s fifty day simple moving average is $0.85 and its 200 day simple moving average is $1.74. Harvard Bioscience has a 52 week low of $0.36 and a 52 week high of $4.45. The company has a quick ratio of 0.91, a current ratio of 2.06 and a debt-to-equity ratio of 0.52. The stock has a market cap of $17.00 million, a PE ratio of -1.17 and a beta of 1.47.

Institutional Trading of Harvard Bioscience

Hedge funds have recently added to or reduced their stakes in the business. Focus Partners Wealth bought a new position in shares of Harvard Bioscience during the fourth quarter valued at about $28,000. Intech Investment Management LLC purchased a new position in Harvard Bioscience in the 4th quarter worth approximately $35,000. Sei Investments Co. bought a new stake in Harvard Bioscience in the fourth quarter valued at approximately $47,000. JPMorgan Chase & Co. boosted its stake in shares of Harvard Bioscience by 63.0% during the third quarter. JPMorgan Chase & Co. now owns 29,501 shares of the medical instruments supplier’s stock valued at $79,000 after purchasing an additional 11,397 shares during the period. Finally, Jane Street Group LLC grew its holdings in shares of Harvard Bioscience by 55.5% in the fourth quarter. Jane Street Group LLC now owns 35,769 shares of the medical instruments supplier’s stock worth $75,000 after purchasing an additional 12,767 shares during the last quarter. 80.87% of the stock is owned by institutional investors.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.